行情

ARMP

ARMP

Armata医药
AMEX

实时行情|Nasdaq Last Sale

3.630
-0.110
-2.94%
已收盘, 16:00 09/21 EDT
开盘
3.740
昨收
3.740
最高
3.840
最低
3.630
成交量
5,736
成交额
--
52周最高
10.48
52周最低
2.560
市值
9,052.43万
市盈率(TTM)
-3.0463
分时
5日
1月
3月
1年
5年
Armata Pharmaceuticals 将参加 HC Wainwright 第 23 届年度全球投资会议
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno...
PR Newswire - PRF · 09/08 12:01
Armata Pharmaceuticals Q2 每股收益(0.25 美元)同比上涨(0.26 美元)
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.25) per share. This is a 3.85 percent increase over losses of $(0.26) per share from the same period last year.
Benzinga · 08/12 20:52
Armata Pharmaceuticals, Inc. (ARMP) 报告第二季度亏损,高于收入预期
Zacks.com · 08/12 08:58
Armata Pharmaceuticals, Inc. (ARMP) 会报告负的第二季度收益吗?你应该知道的
Zacks.com · 08/05 19:00
Armata Pharma 首席执行官卸任
Armata Pharmaceuticals (NYSE:ARMP) announces that its current CEO, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today. The Company's current President and Chief Development Officer,
Seekingalpha · 08/02 12:11
Armata Pharmaceuticals 称首席执行官退休;继任者
MT Newswires · 08/02 10:07
Armata Pharmaceuticals 将出席 Ladenburg Thalmann 2021 医疗保健会议
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno...
PR Newswire - PRF · 07/07 11:30
Arm在剑桥联合创立了“深度技术”启动加速器
Arm has co-founded a new start-up accelerator in Cambridge, England, to try and help young "deep tech" firms to grow into the next generation of tech giants.
CNBC.com · 06/11 12:51
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ARMP最新的财务预测,通过ARMP每股收益,每股净资产,每股现金流等数据分析Armata医药近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ARMP价格均价为7.67,最高价位9.00,最低价为7.00。
EPS
机构持股
总机构数: 13
机构持股: 11.95万
持股比例: 0.48%
总股本: 2,493.78万
类型机构数股数
增持
4
4.38万
建仓
0
0
减持
5
14.72万
平仓
13
3.60万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.43%
制药与医学研究
+0.74%
高管信息
Chief Executive Officer/Director
Brian Varnum
Chief Financial Officer
Steven Martin
Vice President - Operations
Duane Morris
Vice President
Mina Pastagia
Director
Todd Patrick
Independent Director
Jules Haimovitz
Independent Director
Odysseas Kostas
Independent Director
Robin Kramer
Independent Director
Joseph Patti
Independent Director
Todd Peterson
Independent Director
Sarah Schlesinger
暂无数据
ARMP 简况
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. The Company is a developer of synthetic phage platform, which targets therapeutics for the treatment of various multidrug-resistant bacterial infections. It develops synthetic phage products that target a specific pathogen begins with the isolation of natural phages from environmental and clinical samples. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AP-PA02 and AP-SA02.

微牛提供Armata Pharmaceuticals Inc(AMEX-ARMP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ARMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ARMP股票基本功能。